

Review

Collagen-Based Biomaterials for Wound Healing

Sayani Chattopadhyay,¹ Ronald T. Raines^{1,2}

¹ Department of Chemistry, University of Wisconsin–Madison, Madison, WI 53706

² Department of Biochemistry, University of Wisconsin–Madison, Madison, WI 53706

Received 24 February 2014; accepted 7 March 2014

Published online 14 March 2014 in Wiley Online Library (wileyonlinelibrary.com). DOI 10.1002/bip.22486

ABSTRACT:

With its wide distribution in soft and hard connective tissues, collagen is the most abundant of animal proteins. *In vitro*, natural collagen can be formed into highly organized, three-dimensional scaffolds that are intrinsically biocompatible, biodegradable, nontoxic upon exogenous application, and endowed with high tensile strength. These attributes make collagen the material of choice for wound healing and tissue engineering applications. In this article, we review the structure and molecular interactions of collagen *in vivo*; the recent use of natural collagen in sponges, injectables, films and membranes, dressings, and skin grafts; and the on-going development of synthetic collagen mimetic peptides as pylons to anchor cytoactive agents in wound beds. © 2014 Wiley Periodicals, Inc.

Biopolymers 101: 821–833, 2014.

Keywords: biocompatible; biodegradable; catgut; extracellular matrix; regenerative medicine

This article was originally published online as an accepted preprint. The “Published Online” date corresponds to the preprint version. You can request a copy of the preprint by emailing the *Biopolymers* editorial office at biopolymers@wiley.com

Correspondence to: Ronald T. Raines; e-mail: rtraines@wisc.edu

Contract grant sponsor: NIH

Contract grant numbers: R01 AR044276 and RC2 AR058971

© 2014 Wiley Periodicals, Inc.

INTRODUCTION

Collagen has served humanity in myriad ways. This most abundant of animal proteins is the principle component of leathers, glues, gelatin for food and pharmaceutical capsules, and strings for musical instruments and tennis rackets. No other protein has had as much practical utility.

The use of collagen as a modern biomaterial began in 1881.¹ In that year, Joseph Lister, who founded modern surgery, and his former student William Macewen reported independently on the advantages of a biodegradable suture termed “catgut,” a collagen-rich biomaterial prepared from the small intestine of a sheep (Figure 1).^{2,3} Over the ensuing years, countless innovations have extended the reach of collagen in the engineering and repair of soft tissue.^{4–8}

In most soft and hard connective tissues, collagen fibrils and their networks comprise the majority of the extracellular matrix (ECM) and form a highly organized, three-dimensional (3D) scaffold that surrounds the cells. Collagen also plays a dominant role in maintaining the biological and structural integrity of the ECM, and is a dynamic and flexible material that undergoes constant remodeling to refine cellular behavior and tissue function.⁹ Collagen is surface-active and is capable of penetrating a lipid-free interface.¹⁰ Biodegradable and nontoxic, exogenous collagen is more biocompatible than other natural polymers, and only weakly antigenic.¹¹ Collagen can form fibers with high tensile strength and stability via cross-linking and self-aggregation. These fibers can be formulated into numerous scaffolds of high utility (Table I), which have arisen from an in-depth understanding of collagen structure and function. Here, we review modern collagen-based biomaterials for wound healing, and we highlight on-going challenges and unmet needs.

THE COLLAGEN MOLECULE

Collagen accounts for about one-third of the protein of humans and two-thirds of the dry weight of skin. To date, 29 different types of collagen have been identified (type XXIX



FIGURE 1 Sir Joseph Lister (English) and Sir William Macewen (Scottish), pioneers in the use of exogenous collagen in medicine.^{1–3} The image of Lister is from an oil painting by Walter William Oules (courtesy of the Wellcome Library, London); the image of Macewen is from an oil painting by Charles R. Dowell (courtesy of the Royal College of Physicians and Surgeons of Glasgow). The catgut in oil was prepared by Lister in 1875 (courtesy of King's College London).

belongs to the class of collagens containing von Willebrand factor type A domains¹²), and all of them display a triple-helical tertiary structure. Types I–III, V, and XI have fibrillar quaternary structures.

Collagen molecules are comprised of three polypeptide chains.⁵ These chains, aligned in a parallel manner and coiled

Table I Commercial Forms of Reconstituted Collagen

Collagen Form	Name (Company)
Partially purified skin	Gelfoam (Pfizer)
	Helistat (Integra LifeSciences)
	Instat (Johnson & Johnson)
	ActiFoam (MedChem)
Collagen sponge	SkinTemp (BioCor)
	Helitene (Integra LifeScience)
	Instat Fibrillar (Johnson & Johnson)
Collagen fiber	Avitene (Medichem)
	BioCore (Medifil)
	Fibracol (Johnson & Johnson)
Collagen powder	Biobrane (UDL Laboratories)
	Chronicure (Derma Sciences)




FIGURE 2 Structure of triple-helical collagen.⁵ Hydrogen bonds, blue dashed lines; $n \rightarrow \pi^*$ interactions, red dashed lines. Panel A is a cross-section from PDB entry 1v4f.¹³

in a left-handed polyproline II-type (PPII) helix, wrap around each other to form a right-handed triple helix that is stabilized by interstrand hydrogen bonds and intrastrand $n \rightarrow \pi^*$ interactions (Figure 2).¹³ In animals, individual collagen triple helices (tropocollagen) form macroscopic fibers and networks in tissue, bone, and basement membrane.

Each polypeptide chain in a collagen triple helix is composed of a thousand or so amino acid residues. Every third residue is a glycine (Gly), resulting in a Xaa-Yaa-Gly repeat unit, where Xaa and Yaa can be any amino acid (Table II). The repetitive presence of Gly ensures a tight packing of the three strands in a tropocollagen triple helix. The Xaa and Yaa positions are often occupied by two amino acids discovered by Fischer: (2*S*)-proline (Pro)¹⁵ and (2*S*,4*R*)-4-hydroxyproline (Hyp),¹⁶ making Pro-Hyp-Gly the most common triplet in collagen.¹⁷ The 29 different types of collagen are composed of approximately 25 different chains, assembled in combination. Although the three chains in a triple helix can be identical, heterotrimeric triple helices are more prevalent than are homotrimeric ones.

Table II Amino Acid Composition of the Two Polypeptide Chains that Form the $\alpha 1(I)$ - $\alpha 1(I)$ - $\alpha 2(I)$ Triple Helix of Human Type I Collagen¹⁴

Amino Acid	$\alpha 1(I)$ chain	$\alpha 2(I)$ chain
Alanine	124	111
Arginine	53	56
Asparagine	13	23
Aspartic Acid	33	24
Glutamic Acid	52	46
Glutamine	27	24
Glycine	345	346
Histidine	3	8
Hydroxylysine	4	9
Hydroxyproline	114	99
Isoleucine	9	18
Leucine	22	33
Lysine	34	21
Methionine	7	4
Phenylalanine	13	15
Proline	127	108
Serine	37	35
Threonine	17	20
Tyrosine	5	4
Valine	17	34

Proline-hydroxyproline-glycine (bold typeface) is the most common triplet in each chain.

Of the various types of collagen, only a few are used in the production of collagen-based biomaterials. In fibrillar collagen, tropocollagen triple helices assemble into fibrils, which agglomerate to form fibers (Figure 3). These fibril-forming collagens have large sections of homologous sequences,¹⁸ and constitute the most commonly used forms of collagen-based biomaterials for wound healing and tissue engineering purposes. Type I collagen is the most abundant type in animals and is the type most often used in medicine.

COLLAGEN IN VIVO

Collagen can be extracted from the tissue of any animal, even long-extinct dinosaurs.^{19,20} Common sources for biomedical application include bovine skin and tendons; porcine skin, intestine, or bladder mucosa; and rat tail.²¹ The properties of the extracted collagen differ depending on the animal and tissue. The use of collagen derived from animal sources can be complicated by allergic reaction and pathogen transmission.^{11,22} As an alternative, collagen can be produced by heterologous expression in mammalian, insect, and yeast cells.²³ Collagen produced in *Escherichia coli* has special promise.^{24,25}

Many cell-surface proteins bind to collagen.²⁶ Cell-collagen interactions are mediated by four different kinds of proteins: (1) receptors (like glycoprotein VI) that recognize peptide

sequences containing the Pro-Hyp-Gly unit,²⁷ (2) receptors of the integrin family and discoidin domain receptor 1 and 2, which bind to the Phe-Hyp-Gly sequence, (3) receptors of the integrin-type that recognize cryptic motifs within collagen, and (4) receptors with affinity for noncollagenous domains. Many proteins (like decorin and laminin) that contain RGD or a




FIGURE 3 Biosynthetic route to collagen fibers. Size and complexity increase on posttranslational modification and self-assembly. The oxidation of lysine side chains leads to the spontaneous formation of hydroxylysyl pyridinoline and lysyl pyridinoline cross-links.

similar integrin-recognition sequences can bind to both collagen and integrins, promoting cell adhesion and proliferation.²⁸

BIODEGRADABILITY OF COLLAGEN

As befits the primary structural protein in the body, collagen is resistant to proteolysis. Although the peptide bonds in a triple helix are occluded from enzymic active sites, single-stranded regions are cleaved by matrix metalloproteinases (MMPs). Specifically, types I–III are hydrolyzed by MMP-1, MMP-2, MMP-8, MMP-13, and MMP-14, which are collagenases.^{29–32} The ensuing collagen fragments are degraded further by gelatinases and nonspecific proteases. Other MMPs, such as MMP-3 and MMP-9, bind to type I collagen but do not participate in its degradation.^{33,34}

High biocompatibility and intrinsic biodegradability by endogenous collagenases makes exogenous collagen ideal for use in biomedical applications. Exogenous collagen can, however, elicit a complex response. For example, some of the degradation products of collagen types I–III induce chemotaxis of human fibroblasts,³⁵ and such degradation is thought to promote restoration of tissue structure and functionality.³⁶

CROSS-LINKING OF COLLAGEN

The proteolytic resistance and high tensile strength of natural collagen can be attributed largely to its covalent cross-links.³⁷ Damage to such linkages on extraction and overtime weakens reconstituted forms of collagen (e.g., sponges, hydrogels, films, and membranes), which can then disintegrate on handling or under the pressure of surrounding tissues *in vivo*. Hence, efforts have been made to control the rate of degradation as well as *in vivo* absorption by generating new cross-links. Typically, the *in vitro* cross-linking of collagen enlists its amino and carboxyl groups to form new covalent bonds. The techniques can be grouped into three types, as follows.

Chemical Cross-Linking

Collagen has been cross-linked with formaldehyde,³⁸ glutaraldehyde,^{39,40} carbodiimides,^{41,42} polyepoxy compounds,⁴³ acyl azides,⁴⁴ and hexamethylene diisocyanate.⁴⁵ Although chemical cross-linking can enhance stability, residual electrophilic reagents and compounds formed on degradation *in vivo* can be cytotoxic.^{46,47} In an alternative approach, collagen biomaterials are stabilized by exploiting the large number of amino groups on polycationic molecules like chitosan, thereby increasing the cross-linking efficiency of glutaraldehyde and minimizing its use and potential cytotoxicity.⁴⁸ Nontoxic chitosan is mixed with collagen just before lyophilization, simplifying the process.

Physical Cross-Linking Using Ultraviolet Light or Dehydrothermal Treatment

Exposure to either light at 254 nm or dehydrothermal treatment (DHT) increases the temperature for collagen shrinkage, tensile strength of the fibers, and resistance to proteolytic degradation.⁴⁹ UV-irradiation requires only 15 min, whereas DHT treatment takes 3–5 days. UV-irradiation increases proteolytic resistance.³⁷ DHT treatment increases the sensitivity of collagen to trypsin but lowers the propensity for degradation by pepsin and lysosomal cathepsins.⁵⁰

Cross-Linking with Enzymes

Transglutaminase, in particular, can enhance the tensile strength and hydrolytic resistance of collagen-based biomaterials.⁵¹ This method is benign, generating no cytotoxic byproducts.

PREPARATION OF COLLAGEN-BASED MATERIALS

Natural collagen-based biomaterials can be classified into two categories based on the extent of their purification: decellularized collagen matrices that maintain the original tissue properties and ECM structure; and more refined scaffolds prepared via extraction, purification, and collagen polymerization. Decellularizing collagen entails a combination of physical (snap freezing or high pressure), chemical (acid or alkali treatment, chelation with EDTA, or treatment with detergents or solutions of high osmolarity), and enzymatic (digestion with trypsin) methods to produce the biomaterial.⁵² Collagen in this form is used often as sutures, cardiac valves, and ligamentary prostheses. Generating collagen-based scaffolds involves processing collagen solutions with other biomolecules, such as elastin,⁵³ glycosaminoglycans (GAG),⁵⁴ and chitosan.⁴⁰ Different applications require different formulations (Table III). Production of such biomaterials requires the extraction and purification of collagen from natural tissues. The dissolution of collagen is, however, impeded by the low solubility of natural collagen due to its covalent cross-links. Natural collagen is insoluble in organic solvents but can dissolve in aqueous solutions, depending on the extant cross-linking. The most common solvent systems include a neutral salt solution (0.15–0.20M NaCl),⁵⁵ dilute acid solution (0.5M acetic acid), or a solution of proteolytic enzymes, as the collagen triple-helical domain is resistant to proteases like pepsin, chymotrypsin, or ficin below ~20°C.⁵⁶ The telopeptide ends are, however, vulnerable. Pepsin at a 1:10 weight ratio of enzyme to dry tissue in dilute acetic acid provides a medium in which collagen can be swollen and dissolved readily.¹⁴

Table III Biomedical Applications of Collagen

Composition	Biomaterial Form	Applications
Collagen	Gel	Cosmetic skin defects
		Drug delivery
		Vitreous replacement
	Sponge	Surgery Coating of bioprostheses
		3D cell culture
		Wound dressing
		Hemostatic agent
	Hollow fiber tubing	Skin replacement Drug delivery
		Cell culture
	Sphere	Nerve regeneration
Microcarrier for cell culture		
Membrane	Drug delivery	
	Wound dressing	
	Dialysis	
Collagen + GAG	Rigid form	Tissue regeneration
		Corneal shields
	Sponge	Skin patches
		Bone repair
		3D cell culture
Collagen + Hydroxyapatite	Membrane	Wound dressing
		Skin replacement
	Powder sponge	Tissue regeneration
		Skin patches
		Bond-filling and repair drug delivery (BMP)

SPONGES

Commercial collagen sponges are insoluble forms of the protein derived from animals like cows, horses, and pigs. The sponges are prepared by lyophilizing aqueous acid- or alkali-swollen collagen solutions containing 0.1–5% w/v dry matter. Their porosity is controlled by varying the collagen content and freezing rate. These sponges are capable of absorbing large amounts of tissue exudate, adhere smoothly to a wet wound bed, and maintain a moist environment, while shielding against mechanical trauma and bacterial infection.⁵⁷ They are used routinely as a wound dressing for severe burns, pressure sores, donor sites, and leg ulcers, and in *in vitro* experiments.⁵⁸ Collagen sponges have been combined with elastin, fibronectins, and GAGs to impart resilience and fluid-binding capacity.^{59,60} These materials can be cross-linked further with glutaraldehyde and conjugated with polymers like poly(hydroxyethylmethacrylate) to produce hydrophilic matrices with increased mechanical strength. 3D collagen lattices loaded physiologically with fibroblasts have been developed as an *in vitro* model for wound healing.⁶¹ Collagen promotes cellular motility, and inflammatory cells actively invade the porous scaffold.⁶² A highly vascularized granulation tissue forms that, in turn, stimulates the formation of new granulation tissue and epithelial layers. Sponge implantation in burn wounds causes a rapid recovery of the skin due to an intense infiltration of neutrophils in the sponge.⁶³

Collagen sponges are especially useful in wound healing because their wet-strength allows their suturing to soft tissue and provides a template for new tissue growth. Collagen-based implants have been used as vehicles for delivery of cultured keratinocytes and drugs for skin replacement and burn-wound treatment.^{63–65} Implanted collagen sponges are infiltrated by amorphous connective tissue containing GAGs, fibronectin, and new collagen, followed by various cells, primarily fibroblasts and macrophages. When cells are bound to an ECM, such as an implanted collagen sponge, there is an increase in the production of new collagen.³⁵ Depending on the degree of cross-linking, the collagen sponge is degraded by collagenases into peptide fragments and amino acids in 3–6 weeks, and the implant is then replaced by native type I collagen produced by fibroblasts. Chemical composites with other biomaterials, and acetylated, succinylated, or methylated collagen have also been used to immobilize therapeutic enzymes or control drug delivery. One such modification of interest is biotinylation.⁶⁶ After the covalent attachment of biotin, a model protein (horseradish peroxidase) is bound via a pendant avidin. Biotinylation of collagen has also been used to attach peptide growth factors like heparin-binding growth factor and epidermal growth factor, modulating the healing of full-thickness wounds.⁶⁷

Collagen-based sponges are an effective scaffold for the application of exogenous growth factors to wounds. Type I

collagen sponges can expedite wound healing by promoting the deposition of nascent large-diameter collagen fibers parallel to the fibers in the sponge, thereby increasing tensile strength in large open dermal wounds. When these sponges are seeded with fibroblasts or coated with basic fibroblast growth factor (FGF) prior to implantation in a guinea-pig dermal wound model, they promote both early dermal and epidermal wound healing.⁶⁸ Platelet-derived growth factor (PDGF), on introduction into the wound matrix via a collagen sponge scaffold, increases fibroblast influx into the wounds and enhances capillary formation in comparison to control treatments.⁶⁹

Collagen sponges are suitable for short-term delivery of antibiotics in wound bed. Sponges soaked with solutions of gentamicin, cefotaxim, fusidic acid, clindamycin, or vancomycin release 99.9% of these antibiotic agents after 2 days *in vitro*.⁷⁰ Local infection is contained by a gentamicin-containing collagen matrix placed on a septic focus in rat abdomen.⁷¹ These sponges do not exhibit any unwanted side effects and are absorbed into tissue after a few days.⁷²

Apart from acting as a scaffold for growth factors and antibiotics, porous collagen sponges are also of use for cell culture, either for tissue engineering purposes *ex vivo* or as a direct implant. They have been used to promote the formation of cartilage via chondrocytes (with or without FGF),^{73,74} abdominal walls via myoblasts,⁷⁵ and axons in spinal cord from Schwann cells.⁷⁶ Dense type I collagen matrices can also act as a scaffold for *in vitro* fibroblast cell culture⁷⁷ and analyses of angiogenesis.⁷⁸ A combination of collagen biomaterials and mesenchymal stem cells could provide a useful strategy to treat wounds.^{79,80} A modified sponge that can act as an artificial skin graft has been developed by combining fibrillar collagen with gelatin,⁸¹ which is then stabilized via DHT cross-linking. A similar sponge incorporating gelatin has been used as a carrier matrix for mesenchymal stem cells used for cartilage stem cell therapy.⁸²

Sponges formed from synthetic collagen are also known. A freeze-dried sponge composed of a heterogeneous polymer of Pro-Hyp-Gly triplets embedded subcutaneously into the dorsal area of a rat degrades at the same rate as does bovine type I atelocollagen, and promotes greater epithelialization of a full-thickness wound on the ear pad of a rabbit.⁸³ Incorporation of the fibronectin-derived peptides GRGDS and PHSRN into the sponge enhances the adhesion, migration, and stratification of NIH3T3 cells.⁸⁴

INJECTABLES AND HYDROGELS

For several decades, dermatological defects have been treated with subcutaneous injections of collagen solutions. This application is a commercial success, particularly in the area of plas-

tic and reconstructive surgery. An extensive study showed that treating reconstituted pepsin-solubilized bovine corium collagen dispersions with glutaraldehyde has a significant impact on physiochemical stability and that the biological response is a function of the degree of cross-linking.^{65,85} At low glutaraldehyde concentrations, the response is characterized by an influx of fibroblasts, neovascularization, and little inflammation. Treatment of the collagen dispersions with higher concentrations of glutaraldehyde causes a foreign body/giant cell reaction and calcification. The solubility of such treated fibrils decreases at high temperatures, but the proteolytic stability increases compared to noncross-linked fibers. Cross-linking increases the solution viscosity,^{85,86} making the injection of cross-linked formulations into affected tissue difficult. The addition of hyaluronic acid at 0.3–0.5% w/v eased the injection process. A patent indicates that small molecules like maltose and neutral polymers like dextran can be used as lubricants to facilitate injection into tissue.⁸⁷

The delivery of local anesthetics and central analgesics can be prolonged by 5- to 30-fold on formulation with collagen.⁸⁸ This increase could be due to a decrease in the rate of diffusion of the drug due to the high microviscosity of the collagen, or to an affinity of the drug molecule for collagen. Subsequent work shows that fibrillar collagen is capable of moderating the release-rate only of large proteins, like fibrinogen, and significant amounts of nonfibrillar content are necessary to regulate the diffusion of small proteins, like chymotrypsinogen.⁸⁹

The scope for using injectable collagen formulations for the delivery of growth factors and consequent cellular regeneration and tissue repair is vast. In a porcine model, intestinal wound repair is expedited by treatment with collagen suspensions carrying FGF or transforming growth factor- β . These formulations also partially reverse the steroid-induced impairment of breaking-load in intestinal-wound models.⁹⁰ Investigations of cellular function, migration, proliferation, and differentiation in collagen gels has led to further understanding of the mechanism and kinetics of transport, as well as the influence of growth factors, laminin, and fibronectin.^{91–93}

Collagen gels positioned between the stumps of a transected spinal cord cause axons to emerge from the interface with the spinal tissue and then grow into the implanted collagen gel within a month.⁹⁴ The tensile strength and durability of the collagen implant is strengthened by coprecipitation with chondroitin-6-sulfate or cross-linking by carbodiimide, which also regulates the normal scarring process, and promotes axon growth⁹⁴ and fibroblast proliferation.⁹⁵ The efficacy of injectable fluid collagen solution into the lesion that self-assembles *in situ* has been compared to an implanted collagen gel.⁹⁶ Corticospinal tract axons have been visualized in the matrix, along with an

influx of astroglial and microglial cells into the collagen. Conversely, a collagen gel, implanted preassembled, does not show any axon growth or the influx of astroglial and microglial cells.

Collagen hydrogels present a large, uniform surface area, and can serve as a drug delivery system. A common practice has been to combine natural and synthetic polymers with synergistic properties, thereby imparting higher mechanical strength to the natural polymers and biocompatibility to their synthetic counterparts. Synthetic polymers like poly(vinyl alcohol) and poly(acrylic acid) are blended with natural polymers like collagen and hyaluronic acid, and formulated into hydrogels, films, and sponges that are then loaded with growth hormone.⁹⁷ These formulations provide a controlled-release of growth hormone from the collagen hydrogel. Gels have also been formulated with atelocollagen, produced by the removal of telopeptide ends using pepsin, and used for the delivery of chondrocytes to repair cartilage defects.⁹⁸

Liposomes sequestered in a collagen gel can release insulin or growth hormone into circulation in a controlled manner.⁹⁹ The collagen decreases lipid peroxidation, as well as the permeability of neutral or negatively charged liposomes, resulting in the slow diffusion of the encapsulated compound over a period of 3–5 days.^{99,100} A patent suggests that collagen can also be used as an additive in oil-based suspensions, to sustain the release of proteins that had been lyophilized and suspended in a lipophilic liquid.¹⁰¹ This technology could have potential as a topical treatment for surgical and nonsurgical wounds and burns.

FILMS AND MEMBRANES

Collagen films have been used in wound healing and tissue engineering, primarily as a barrier. Films of ~0.1–0.5 mm thickness can be cast from collagen solutions and air dried in a manner similar to ophthalmological shields. As an added advantage, films made from biodegradable materials like telopeptide-free reconstituted collagen demonstrate a slow release of encapsulated drugs.¹⁰² The loaded films afford easy sterilization and become pliable after hydration, without compromise to their mechanical strength.

Collagen membranes have been used for wound dressings, dural closures, reinforcement of compromised tissues, and guided tissue regeneration. Wound healing in diabetic *db/db* mice has been modulated by a sustained release of human growth hormone encapsulated in collagen films.¹⁰³ Likewise, films made with collagen–poly(vinyl alcohol) mixtures cross-linked with glutaraldehyde vapors have been tested as a formulation for delivering recombinant human growth hormone.⁹⁷ A patent describes single and multilayer collagen films as vehicles for the sustained release of pharmaceuticals, especially

growth factors.¹⁰⁴ Individual collagen films are attached together by applying gentle pressure to form multilayer membranes, and PDGF is released from these films at a constant rate for up to 100 h, improving wound healing *in vivo*.

Biodegradable collagen membranes can be scaffolds for viable fibroblasts.¹⁰⁵ A blend of collagen and another polymer, such as an atelocollagen matrix, added on the surface of polyurethane films promotes the attachment and proliferation of fibroblasts, supports their growth, and enhances long-term survival.¹⁰⁶ In addition, recombinant type I collagen from *Pichia pastoris* yeast has been used to formulate films for tissue engineering and guided tissue regeneration after dental surgery.¹⁰⁷

WOUND DRESSINGS

Collagen plays a pivotal role in many preoperative and postoperative surgical procedures. Due to its low antigenicity and inherent biocompatibility with most endogenous tissue, natural collagen has often been used for surgical repair.¹⁰⁸ Wound dressings based on collagen are practical and easily remodeled due to their simple structure, relative uniformity, and abundant availability. These attributes have led to the development of novel surgical adhesives synthesized from porcine collagen and poly(glutamic acid).¹⁰⁹ These adhesives have been used to prevent air from leaking out of damaged lungs. The absorption of such collagen-based adhesives can be regulated by altering the collagen content of the system.

Collagen-based wound dressings have long been used to cover burn wounds and treat ulcers.^{36,56,110} They have a distinctive practical and economic advantage compared to growth-factor and cell-based treatment of full-thickness wounds and have been formulated in a number of different ways (Table I). An unconventional form consisting of powdered avian collagen is effective at expediting chronic wound healing.¹¹¹ The powder promotes cellular recruitment, activation of the inflammation phase of wound healing, and support for new tissue growth—similar in function to collagen sponges.

Some common, commercial skin, dermal substitutes, and dressings like AllodermTM (human dermis), AmniographTM (amniotic membrane), Integra[®] (acellular collagen-GAG scaffold), and OasisTM (porcine skin), are used for medical applications. A combination of collagen with alginate has also been successful in promoting the inflammatory phase of wound healing, while imparting mechanical strength—a characteristic of collagen fibrils.

Collagen dressings have been prepared with a semioclusive polymer film attached to its outer surface.¹¹² Such occlusive films are resistant to bacterial attack as well as further mechanical trauma and provide proper air and vapor permeability.

They reduce contraction and scarring and increase the rate of epithelialization. One such dressing used extensively in burn care is Biobrane[®], which consists of a silicone membrane knitted with a nylon membrane, both of which are impregnated with fragments of porcine collagen. Used as a temporary dressing, this composite promotes granulation and acts as an adjunct therapy for full-thickness wounds.^{113,114}

SKIN REPLACEMENT

Due to its mechanical strength and biocompatibility, reconstituted type I collagen can replace damaged skin directly.¹¹⁵ For example, a full-thickness excision wound in a porcine model has been used to study the effects of a collagen matrix implant on granulation tissue formation, wound contraction, and re-epithelialization.⁶⁴ Wounds with implants show enhanced granulation tissue formation and re-epithelialization; contraction is reduced significantly, showing a bias toward wound regeneration and cosmetic utility.

Cultured skin substitutes from cryo-preserved skin cells have been used to cure chronic diabetic wounds.¹¹⁶ *In lieu* of pathological skin, the contracted collagen lattice serves as a support for epithelial cell growth and differentiation.¹¹⁷ Collagen implants have also been used in corneal healing, and corneal cells have a normal appearance when cultured individually on a synthetic collagen matrix.¹¹⁸

Corneal scaffolds have been constructed with recombinant human collagen¹¹⁹ and can induce collagen secretion by fibroblasts.¹²⁰ Microbial baggage control has been attempted by the addition of antimicrobial drugs, such as amikacin, to bovine skin collagen.¹²¹ Cutaneous models with melanocytes,¹²² dendritic cells,¹²³ and adipose tissue⁸⁰ have been developed as well.

Cultured skin substitutes exhibit delayed keratinization after grafting in comparison to native skin autografts.¹²⁴ To address this issue, collagen-based systems have been modified with other proteins, such as fibrin, and with GAGs. Human epidermal keratinocytes have been cultured on membranes composed of GAGs and collagen.⁶³ Keratinocytes and fibroblasts have been attached to those membranes, which can be cross-linked to reduce their rate of biodegradation.^{39,125} Incubating collagen-substitutes at low humidity *in vitro* stimulates restoration of a functional epidermis.¹²⁴ Similarly, cultured cells are best grafted in combination with a thin layer of either collagen or fibrin, but not both.¹²⁶

Acellular bilayer artificial skin with an outer layer composed of silicone and an inner layer composed of collagen matrix is compatible with long-term post-operative tissue.¹²⁷ A bilayered-collagen gel seeded with human fibroblasts in the lower part and human keratinocytes in the upper layer has been used as the “dermal” matrix of an artificial skin. This

product has been commercialized by Organogenesis as Apligraf[®], and in 1998 became the first bioengineered skin to receive FDA approval. Organogenesis is developing other collagen-based products, including Revitix[™] (a topical cosmetic product), VCTO1[™] (a bilayered bioengineered skin), and Forta-Derm[™] Antimicrobial (an antimicrobial wound dressing).

COLLAGEN MIMETIC PEPTIDES

Synthetic peptides have provided much insight on the atomic underpinnings of collagen structure and stability.^{5,7,128–134} Using such peptides in wound-healing therapies requires their assembly into larger entities. Peptide–amphiphile conjugates provide a simple means to achieve that end. A short collagen mimetic peptide self-assembles into cylindrical nanofibers that are ~7 nm in diameter and several micrometers in length due to alkyl chains at its N terminus.^{135,136} The peptide domain can display useful functionality on its fibrous surface. For example, a phosphoserine residue stimulates formation of calcium phosphate minerals and an RGD segment promotes the adhesion and growth of cells.

The self-assembly of amphiphilic peptides in a physiological medium can cross-link nanofibrillar collagen gels.¹³⁷ The gels have a high water content and a matrix composed of interwoven nanofibers that are ~10 nm in diameter with ~200-nm pores.¹³⁸ These gels maintain the morphology of differentiated chondrocytes and develop a cartilage-like ECM rich in proteoglycans and type II collagen, thereby showing potential for cartilage repair.¹³⁹

Native chemical ligation has been used to polymerize collagen mimetic peptide in aqueous solution.¹⁴⁰ The resulting 10³-kDa strands form fiber-like structures that are micrometers in length. The presence of cysteine residues in these peptides can be exploited for cross-linking and covalent modification. Collagen-like supramolecules have also been created by the self-assembly of strands mediated by Coulombic forces^{141,142} or the hydrophobic effect,^{143,144} or fragments in which strands are cross-linked by disulfide bonds.^{145,146}

Peptoid-containing collagen mimetic peptides interact with epithelial cells and fibroblasts when immobilized on a synthetic surface.¹⁴⁷ Cell-binding requires a minimum of nine Gly-Pro-Nleu triplets, and such peptides are not cytotoxic. Amine-functionalized latex nanoparticles functionalized with 10 Gly-Pro-Hyp triplets are capable of inducing human platelet aggregation with a potency close to that of type I collagen,¹⁴⁸ and these Gly-Pro-Hyp triplets represent functional platelet–collagen receptor recognition motifs within collagen.²⁷ Thus, these peptides can play active roles in the wound-healing process. A short peptide, (Pro-Pro-Gly)₅, has also been established as a




FIGURE 4 Pyrrolidine ring pucker preferred in the Xaa and Yaa positions of collagen strands, and natural and nonnatural derivatives of proline with those preferences.⁵ The pyrrolidine rings actually prefer a twist rather than envelope conformation. As C^γ typically experiences the largest out-of-plane displacement in these twisted rings, we refer to pyrrolidine ring conformations simply as “C^γ-exo” and “C^γ-endo.”

potent chemoattractant for alveolar macrophages that induces the migration of polymorphonuclear leucocytes into lungs.^{149–151} Coating with peptides mimicking segments of type I collagen promoted mesenchymal cell adhesion to a hydroxyapatite surface and improved bone formation.¹⁵²

A desirable attribute of collagen mimetic peptides is their ability to anneal to endogenous collagen strands but not triple helices (Figure 5). Collagen mimetic peptides containing Pro-Hyp-Gly triplets bind to collagen films¹⁵⁵ and show promise for imaging and wound-healing studies.¹⁵⁶ Gold-nanoparticles functionalized with (Pro-Hyp-Gly)_n peptides bind to the “gap” regions of native collagen.¹⁵⁷ (Pro-Hyp-Gly)_n peptides have, however, a bias to be in a homotrimeric triple helix at room temperature, mandating preheating to high temperatures (~80°C) to generate single strands. Photodeprotection circumvents this limitation, enabling the imaging of (presumably) denatured collagen in tissues that are either undergoing normal renewal processes or suffering from pathological conditions, such as tumor progression or Marfan syndrome, which is a musculoskeletal disease.^{158,159}

The conformational stability of a synthetic collagen triple helix can be increased by having (2*S*,4*S*)-4-fluoroproline (flp) and (2*S*,4*R*)-4-fluoroproline (Flp) in the Xaa and Yaa positions of the Xaa-Yaa-Gly repeat unit.^{160,161} Interestingly, the stability endowed by Flp promotes the adhesion and spreading of melanoma cells.¹⁶² The increased stability derived from nonnatural Pro-Flp-Gly or flp-Pro-Gly triplets arises from an F–C–N *gauche* effect, which preorganizes pyrrolidine ring pucker and thus main-chain dihedral angles (Figure 4).^{161,163–165} Remarkably, (flp-Flp-Gly)_n peptides, unlike

(Pro-Flp-Gly)_n or (flp-Pro-Gly)_n peptides, do not form stable homotrimeric triple helices due to interstrand steric clashes between fluoro groups within the same cross-section of a triple helix.¹⁶⁶ Natural collagen lacks fluoro groups in all of its triplets and Hyp in most (Table II). Thus, (flp-Flp-Gly)₇-dye conjugates anneal strongly to (presumably) damaged collagen both in vitro and ex vivo (Figure 5).¹⁵³ No preheating or photodeprotection of the peptide is necessary, and a (flp-Flp-Gly)₇-dye conjugate at ≥0.1 mM is not toxic to human fibroblast cells.

Finally, we note that a collagen mimetic peptide can act as a pylon, anchoring a pendant molecule in damaged tissue (Figure 5). This strategy has been used to promote wound healing in mice.¹⁵⁴ The administration of exogenous cytoactive factors by subcutaneous or intraperitoneal injection or by topical application is compromised by natural lavation that rapidly dilutes and ultimately drains soluble molecules. In contrast, the one-time application of a collagen mimetic peptide–Substance P conjugate enhances wound healing compared to unconjugated Substance P and other controls, and does so with extensive re-epithelialization and mitigated inflammatory activity. These data validate a simple and general strategy for re-engineering wound beds by the integration of beneficial cytoactive factors.

CONCLUSIONS

An area of foremost importance and urgency in health care research is the development of biomaterials that are accessible, persistent, and versatile. Collagen by virtue of its ubiquity, low




FIGURE 5 Strategy for anchoring molecules in a wound bed. A natural strand (yellow) in weak or damaged collagen is displaced by a synthetic collagen mimetic peptide (CMP; red) that forms a hyperstable triple helix. A pendant dye enables wound assessment,¹⁵³ a pendant growth factor expedites wound healing.¹⁵⁴

immunogenicity, and ability to be molded into strong, biocompatible scaffolds, meets these criteria and thus plays a leading role in wound care. Moreover, collagen-based materials are adroitly at the interface of natural and synthetic macromolecules.

Collagen is likewise important in a related area of wound care—the controlled-release of bioactive molecules. Complementary to the use of heterogeneous collagen composites, the development and use of collagen mimetic peptides as a potent system for targeted delivery of therapeutic molecules to the wound site, can expedite progress in the field of wound healing and tissue regeneration.

REFERENCES

- Gibson, T. *Br J Surg* 1990, 77, 824–825.
- Macewen, W. *Br Med J* 1881, 1, 150–151.
- Lister, J. *Br Med J* 1881, 1, 183–185.
- Stenzel, K. H.; Miyata, T.; Rubin, A. L. *Annu Rev Biochem* 1974, 231–253.
- Shoulders, M. D.; Raines, R. T. *Annu Rev Biochem* 2009, 78, 929–958.
- Parenteau-Bareil, R.; Gauvin, R.; Berthod, F. *Materials* 2010, 3, 1863–1887.
- Yu, S. M.; Li, Y.; Kim, D. *Soft Matter* 2011, 7, 7927–7938.
- Li, Y.; Yu, S. M. *Curr Opin Chem Biol* 2013, 17, 968–975.
- Aszódi, A.; Legate, K. R.; Nakchbandi, I.; Fässler, R. *Annu Rev Cell Dev Biol* 2006, 22, 591–621.
- Fonseca, J. M.; Alsina, A. M.; Francesca, R. *Biochim Biophys Acta Biomembr* 1996, 1279, 259–265.
- Maeda, M.; Tani, S.; Sano, A.; Fujioka, K. *J Control Release* 1999, 62, 313–324.
- Söderhäll, C.; Marenholz, I.; Kersch, T.; Rüschemdorf, F.; Esparza-Gordillo, J.; Worm, M.; Gruber, C.; Mayr, G.; Albrecht, M.; Rohde, K.; Schulz, H.; Wahn, U.; Hubner, N.; Lee, Y. -A. *PLoS Biol* 2007, 5, 1952–1961.
- Okuyama, K.; Hongo, C.; Fukushima, R.; Wu, G.; Narita, H.; Noguchi, K.; Tanaka, Y.; Nishino, N. *Biopolymers* 2004, 76, 367–377.
- Piez, K. A. In *Encyclopedia of Polymer Science and Engineering*; Wiley: New York, NY, 1985, pp 699–727.
- Fischer, E. *Z Physiol Chem* 1901, 33, 151–176.
- Fischer, E. *Berichte* 1902, 35, 2660–2665.
- Ramshaw, J. A. M.; Shah, N. K.; Brodsky, B. *J Struct Biol* 1998, 122, 86–91.
- Timpl, R. In *Extracellular Matrix Biochemistry*; Piez, K. A.; Reddi, A. H., Eds.; Elsevier: New York, 1984, pp 159–190.
- Asara, J. M.; Schweitzer, M. H.; Freimark, L. M.; Phillips, M.; Cantley, L. C. *Science* 2007, 316, 280–285.
- Schweitzer, M. H.; Zheng, W.; Organ, C. L.; Avci, R.; Suo, Z.; Freimark, L. M.; Lebleu, V. S.; Duncan, M. B.; Vander Heiden, M. G.; Neveu, J. M.; Lane, W. S.; Cottrell, J. S.; Horner, J. R.; Cantley, L. C.; Kalluri, R.; Asara, J. M. *Science* 2009, 324, 626–631.
- Badylak, S. F. *Transplant Immunol* 2004, 12, 367–377.
- Koide, T. *Philos Trans R Soc Lond B Biol Sci* 2007, 362, 1281–1291.
- Olsen, D.; Yang, C.; Bodo, M.; Chang, R.; Leigh, S.; Baez, J.; Carmichael, D.; Perälä, M.; Hämäläinen, E. -R.; Jarvinen, M.; Polarek, J. *Adv Drug Deliv Rev* 2003, 55, 1547–1567.
- Buechter, D. D.; Paoletta, D. N.; Lelie, B. S.; Brown, M. S.; Mehos, K. A.; Gruskin, E. A. *J Biol Chem* 2003, 278, 645–650.
- Pinkas, D. M.; Ding, S.; Raines, R. T.; Barron, A. E. *ACS Chem Biol* 2011, 6, 320–324.
- Orgel, J. P.; San Antonio, J. D.; Antipova, O. *Connect Tissue Res* 2011, 52, 2–17.
- Smethurst, P. A.; Onley, D. J.; Jarvis, G. E.; O'Connor, M. N.; Knight, C. G.; Herr, A. B.; Ouwehand, W. H.; Farndale, R. W. *J Biol Chem* 2007, 282, 1296–1304.
- Fiedler, L. R.; Schönherr, E.; Waddington, R.; Niland, S.; Seidler, D. G.; Aeschlimann, D.; Eble, J. A. *J Biol Chem* 2008, 283, 17406–17415.
- Fields, G. B. *J Theor Biol* 1991, 153, 585–602.
- Aimes, R. T.; Quigley, J. P. *J Biol Chem* 1995, 270, 5872–5876.
- Ohuchi, E.; Imai, K.; Fujii, Y.; Sato, H.; Seiki, M.; Okada, Y. *J Biol Chem* 1997, 272, 2446–2451.
- Lauer-Fields, J. L.; Juska, D.; Fields, G. B. *Biopolymers* 2002, 66, 19–32.
- Allan, J. A.; Hembry, R. M.; Angal, S.; Reynolds, J. J.; Murphy, G. *J Cell Sci* 1991, 99, 789–795.
- Allan, J. A.; Docherty, A. J.; Barker, P. J.; Huskisson, N. S.; Reynolds, J. J.; Murphy, G. *Biochem J* 1995, 309, 299–306.
- Postlethwaite, A. E.; Seyer, J. M.; Kang, A. H. *Proc Natl Acad Sci USA* 1978, 75, 871–875.
- Yannas, I.; Burke, J.; Orgill, D.; Skrabut, E. *Science* 1982, 215, 174–176.
- Weadock, K. S.; Miller, E. J.; Keuffel, E. L.; Dunn, M. G. *J Biomed Mater Res* 1996, 32, 221–226.
- Ruderman, R. J.; Wade, C. W. R.; Shepard, W. D.; Leonard, F. J. *Biomater Med Res* 1973, 7, 263–265.
- Harriger, M. D.; Supp, A. P.; Warden, G. D.; Boyce, S. T. *J Biomed Mater Res* 1997, 35, 137–145.
- Wu, X.; Black, L.; Santacana-Laffitte, G.; Patrick, C. W. *J Biomed Mater Res* 2007, 81A, 59–65.
- Powell, H. M.; Boyce, S. T. *Biomaterials* 2006, 27, 5821–5827.
- Powell, H. M.; Boyce, S. T. *Biomaterials* 2007, 28, 1084–1092.
- Tu, R.; Lu, C. L.; Thyagarajan, K.; Wang, E.; Nguyen, H.; Shen, S.; Hata, C.; Quijano, R. C. *J Biomed Mater Res* 1993, 27, 3–9.
- Petite, H.; Rault, I.; Huc, A.; Menasche, P.; Herbage, D. *J Biomed Mater Res* 1990, 24, 179–187.
- Zeugolis, D. I.; Paul, G. R.; Attenburrow, G. *J Biomed Mater Res* 2009, 89A, 895–908.
- Speer, D. P.; Chvapil, M.; Eskelson, C. D.; Ulrich, J. *J Biomed Mater Res* 1980, 14, 753–764.
- van Luyn, M. J. A.; van Wachem, P. B.; Damink, L. H. H. O.; Dijkstra, P. J.; Feijen, J.; Nieuwenhuis, P. *Biomaterials* 1992, 13, 1017–1024.
- Maa, L.; Gao, C.; Maa, Z.; Zhou, J.; Shena, J.; Hub, X.; Han, C. *Biomaterials* 2003, 24, 4833–4841.
- Weadock, K. S.; Miller, E. J.; Bellincampi, L. D.; Zawadsky, J. P.; Dunn, M. G. *J Biomed Mater Res* 1995, 29, 1373–1379.

50. Gorham, S. D.; Light, N. D.; Diamond, A. M.; Willins, M. J.; Bailey, A. J.; Wess, T. J.; Leslie, N. J. *Int J Biol Macromol* 1992, 14, 129–138.
51. Khew, S. T.; Yang, Q. J.; Tong, Y. W. *Biomaterials* 2008, 29, 3034–3045.
52. Gilbert, T. W.; Sellaro, T. L.; Badylak, S. F. *Biomaterials* 2006, 27, 3675–3683.
53. Buijtenhuijs, P.; Buttafoco, L.; Poot, A. A.; Daamen, W. F.; van Kuppevelt, T. H.; Dijkstra, P. J.; de Vos, R. A. I.; Sterk, L. M.; Geelkerken, B. R. H.; Feijen, J.; Vermes, I. *Biotechnol Appl Biochem* 2004, 39, 141–149.
54. Ellis, D. L.; Yannas, I. V. *Biomaterials* 1996, 17, 291–299.
55. Fielding, A. M. In *The Methodology of Connective Tissue Research*; Hall, D. A., Ed.; Joynson-Bruvvers: Oxford, UK, 1976, pp 9–12.
56. Piez, K. A. In *Extracellular Matrix Biochemistry*; Piez, K. A.; Reddi, A. H., Eds.; Elsevier: New York, 1984, pp 1–40.
57. Yannas, I. V. *Angew Chem Int Ed* 1990, 29, 20–35.
58. Geesin, J. C.; Brown, L. J.; Liu, Z.; Berg, R. A. *J Biomed Mater Res* 1996, 33, 1–8.
59. Doillon, C. J.; Silver, F. H. *Biomaterials* 1986, 7, 3–8.
60. Lefebvre, F.; Gorecki, S.; Bareille, R.; Amedee, J.; Bordenave, L.; Rabaud, M. *Biomaterials* 1992, 13, 28–33.
61. Carlson, M. A.; Longaker, M. T. *Wound Repair Regen* 2004, 12, 134–147.
62. Chvapil, M.; Chvapil, T. A.; Owen, J. A. *J Surg Res* 1986, 41, 410–418.
63. Boyce, S. T.; Christianson, D. J.; Hansbrough, J. F. *J Biomed Mater Res* 1988, 22, 939–957.
64. Leipziger, L. S.; Glushko, V.; DiBernardo, B.; Shafaie, F.; Noble, J.; Nichols, J.; Alvarez, O. M. *J Am Acad Dermatol* 1985, 12, 409–419.
65. McPherson, J. M.; Sawamura, S.; Armstrong, R. *J Biomed Mater Res* 1986, 20, 93–107.
66. Boyce, S. T.; Stompro, B. E.; Hansbrough, J. F. *J Biomed Mater Res* 1992, 26, 547–553.
67. Stompro, B. E.; Hansbrough, J. F.; Boyce, S. T. *J Surg Res* 1989, 46, 413–421.
68. Marks, M. G.; Doillon, C.; Silvert, F. H. *J Biomed Mater Res* 1991, 25, 683–696.
69. Lepistö, J.; Kujari, H.; Niinikoski, J.; Laato, M. *Eur Surg Res* 1994, 26, 267–272.
70. Wachol-Drewek, Z.; Pfeiffer, M.; Scholl, E. *Biomaterials* 1996, 17, 1733–1738.
71. Vaneerdeweg, W.; Bresseleers, T.; Du Jardin, P.; Lauwers, P.; Pauli, S.; Thyssens, K.; Van Marck, E.; Elseviers, M.; Eyskens, E. *Eur J Surg* 1998, 164, 617–621.
72. Stemberger, A.; Grimm, H.; Bader, F.; Rahn, H. D.; Ascherl, R. *Eur J Surg* 1997, 578, 17–26.
73. Fujisato, T.; Sajiki, T.; Liu, Q.; Ikada, Y. *Biomaterials* 1996, 17, 155–162.
74. Toolan, B. C.; Frenkel, S. R.; Pachence, J. M.; Yalowitz, L.; Alexander, H. *J Biomed Mater Res* 1996, 31, 273–280.
75. van Wachem, P. B.; van Luyn, M. J. A.; Ponte da Costa, M. L. *J Biomed Mater Res* 1996, 30, 353–360.
76. Paíno, C. L.; Fernandez-Valle, C.; Bates, M. L.; Bunge, M. B. *J Neurocytol* 1994, 23, 433–452.
77. Sung, K. E.; Su, G.; Pehlke, C.; Trier, S. M.; Eliceiri, K. W.; Keely, P. J.; Friedl, A.; Beebe, D. J. *Biomaterials* 2009, 30, 4833–4841.
78. Cross, V. L.; Zheng, Y.; Won Choi, N.; Verbridge, S. S.; Sutermeister, B. A.; Bonassar, L. J.; Fischbach, C.; Stroock, A. D. *Biomaterials* 2010, 31, 8596–8607.
79. Altman, A. M.; Matthias, N.; Yan, Y.; Song, Y. -H.; Bai, X.; Chiu, E. S.; Slakey, D. P.; Alt, E. U. *Biomaterials* 2008, 29, 1431–1442.
80. Trottier, V.; Marceau-Fortier, G.; Germain, L.; Vincent, C.; Fradette, J. *Stem Cells* 2008, 26, 2713–2723.
81. Koide, M.; Osaki, K.; Konishi, J.; Oyamada, K.; Katakura, T.; Takahashi, A.; Yoshizato, K. *J Biomed Mater Res* 1993, 27, 79–87.
82. Ponticello, M. S.; Schinagl, R. M.; Kadiyala, S.; Barry, F. P. *J Biomed Mater Res* 2000, 52, 246–255.
83. Tanihara, M.; Kajiwara, K.; Ida, K.; Suzuki, Y.; Kamitakahara, M.; Ogata, S. -I. *J Biomed Mater Res A* 2007, 85, 133–139.
84. Shibasaki, Y.; Hirohara, S.; Terada, K.; Ando, T.; Tanihara, M. *Biopolymers (Pept Sci)* 2011, 96, 302–315.
85. McPherson, J. M.; Ledger, P. W.; Sawamura, S.; Conti, A.; Wade, S.; Reihanian, H.; Wallace, D. G. *J Biomed Mater Res* 1986, 20, 79–92.
86. Wallace, D. G.; Rhee, W.; Reihanian, H.; Ksander, G.; Lee, R.; Braun, W. B.; Weiss, B. A.; Pharriss, B. B. *J Biomed Mater Res* 1989, 23, 931–945.
87. Wallace, D. G.; Reihanian, H.; Pharriss, B. B.; Braun, W. G. *US Pat* 4803075, 1989.
88. Horáková, Z.; Krajčec, M.; Chvapil, M.; Boissier, J. *Therapie* 1967, 22, 1455–1460.
89. Rosenblatt, J.; Rhee, W.; Wallace, D. *J Control Release* 1989, 9, 195–203.
90. Slavin, J.; Nash, J. R.; Kingsnorth, A. N. *Br J Surg* 1992, 79, 69–72.
91. Saltzman, W. M.; Parkhurst, M. R.; Parsons-Wingterter, P.; Zhu, W. H. *Ann NY Acad Sci* 1992, 665, 259–273.
92. Parkhurst, M. R.; Saltzman, W. M. *Biophys J* 1992, 61, 306–315.
93. Parkhurst, M. R.; Saltzman, W. M. *Cell Immunol* 1994, 156, 77–94.
94. Marchand, R.; Woerly, S.; Bertrand, L.; Valdes, N. *Brain Res Bull* 1993, 30, 415–422.
95. Docherty, R.; Forrester, J. V.; Lackie, J. M.; Gregory, D. W. *J Cell Sci* 1989, 92, 263–270.
96. Joosten, E. A. J.; Bär, P. R.; Gispen, W. H. *J Neurosci Res* 1995, 41, 481–490.
97. Cascone, M. G.; Sim, B.; Sandra, D. *Biomaterials* 1995, 16, 569–574.
98. Uchio, Y.; Ochi, M.; Matsusaki, M.; Kurioka, H.; Katsube, K. *J Biomed Mater Res* 2000, 50, 138–143.
99. Weiner, A. L.; Carpenter-Green, S. S.; Soehngen, E. C.; Lenk, R. P.; Popescu, M. C. *J Pharm Sci* 1985, 74, 922–925.
100. Pajean, M.; Herbage, D. *Int J Pharm* 1993, 91, 209–216.
101. Yamahira, Y.; Fujioka, K.; Sato, S.; Yoshida, N. *Eur Pat EP0140255*, 1985.
102. Rubin, A. L.; Stenzel, K. H.; Miyata, T.; White, M. J.; Dunn, M. *J Clin Pharmacol* 1973, 13, 309–312.

103. Maeda, M.; Kadota, K.; Kajihara, M.; Sano, A.; Fujioka, K. *J Control Release* 2001, 77, 261–272.
104. Song, S. -Z.; Morawiecki, A.; Pierce, G. F.; Pitt, C. G. *US Pat* 5418222, 1995.
105. Rosenthal, F. M.; Kohler, G. *Anticancer Res* 1997, 17, 1179–1186.
106. Park, J. -C.; Hwang, Y. -S.; Lee, J. -E.; Park, K. D.; Matsumura, K.; Hyon, S. -H.; Suh, H. *J Biomed Mater Res* 2000, 52, 669–677.
107. Yang, C.; Hillas, P. J.; Báez, J. A.; Nokelainen, M.; Balan, J.; Tang, J.; Spiro, R.; Polarek, J. W. *BioDrugs* 2004, 18, 103–119.
108. Van der Laan, J. S.; Lopez, G. P.; van Wachem, P. B.; Nieuwenhuis, P.; Ratner, B. D.; Bleichrodt, R. P.; Schakenraad, J. M. *Int J Artif Organs* 1991, 14, 661–666.
109. Sekine, T.; Nakamura, T.; Shimizu, Y.; Ueda, H.; Matsumoto, K.; Takimoto, Y.; Kiyotani, T. *J Biomed Mater Res* 2001, 54, 305–310.
110. Peters, W. *J. Ann Plast Surg* 1980, 4, 133–137.
111. Whitaker, K.; Barrow, P.; Feree, K. *Ostomy Wound Manage* 1992, 38, 36–44.
112. Zitelli, J. A. *Adv Dermatol* 1987, 2, 243.
113. Smith, D. J., Jr. *J Burn Care Res* 1995, 16, 317–320.
114. Lal, S.; Barrow, R. E.; Wolf, S. E.; Chinkes, D. L.; Hart, D. W.; Hegggers, J. P.; Herndon, D. N. *Shock* 2000, 14, 314–319.
115. Rao, K. P. *J Biomater Sci* 1996, 7, 623–645.
116. Boyce, S. *Med Biol Eng Comput* 1998, 36, 791–800.
117. Yannas, I. V.; Lee, E.; Orgill, D. P.; Skrabut, E. M.; Murphy, G. F. *Proc Natl Acad Sci USA* 1989, 86, 933–937.
118. Orwin, E. J.; Hubel, A. *Tissue Eng* 2000, 6, 304–319.
119. Griffith, M.; Jackson, W. B.; Lagali, N.; Merrett, K.; Li, F.; Fagerholm, P. *Eye* 2009, 23, 1985–1989.
120. Carrier, P.; Deschambeault, A.; Talbot, M.; Giasson, C. J.; Auger, F. A.; Guérin, S. L.; Germain, L. *Invest Ophthalmol Vis Sci* 2008, 49, 1376–1385.
121. Boyce, S. T.; Supp, A. P.; Warden, G. D.; Holder, I. A. *Antimicrob Agents Chemother* 1993, 37, 1890–1895.
122. Régnier, M.; Staquet, M.-J.; Schmitt, D.; Schimdt, R. *J Invest Dermatol* 1997, 109, 510–512.
123. Bechetoille, N.; Dezutter-Dambuyant, C.; Damour, O.; André, V.; Orly, I.; Perrier, E. *Tissue Eng* 2007, 13, 2667–2679.
124. Supp, A. P.; Wickett, R. R.; Swope, V. B.; Harriger, M. D.; Hoath, S. B.; Boyce, S. T. *Wound Repair Regen* 1999, 7, 226–237.
125. Boyce, S. T.; Goretsky, M. J.; Greenhalgh, D. G.; Kagan, R. J.; Rieman, M. T.; Warden, G. D. *Ann Surg* 1995, 222, 743–752.
126. Lam, P. K.; Chan, E. S. Y.; Liew, C. T.; Lau, C. H.; Yen, S. C.; King, W. W. K. *Ann Plast Surg* 1999, 43, 523–528.
127. Suzuki, S.; Kawai, K.; Ashoori, F.; Morimoto, N.; Nishimura, Y.; Ikada, Y. *Br J Plast Surg* 2000, 53, 659–666.
128. Koide, T. *Philos Trans R Soc Lond B Biol Sci* 2007, 362, 1281–1291.
129. Woolfson, D. N. *Biopolymers* 2010, 94, 118–127.
130. Fields, G. B. *Org Biomol Chem* 2010, 8, 1237–1258.
131. Fallas, J. A.; O’Leary, L. E.; Hartgerink, J. D. *Chem Soc Rev* 2010, 39, 3510–3527.
132. Przybyła, D. E.; Chmielewski, J. *Biochemistry* 2010, 49, 4411–4419.
133. Siebler, C.; Erdmann, R. S.; Wennemers, H. *Chimia* 2013, 67, 891–895.
134. He, L.; Theato, P. *Eur Polym J* 2013, 49, 2986–2997.
135. Hartgerink, J. D.; Beniash, E.; Stupp, S. I. *Science* 2001, 294, 1684–1688.
136. Hartgerink, J. D.; Beniash, E.; Stupp, S. I. *Proc Natl Acad Sci USA* 2002, 99, 5133–5138.
137. Zhang, S. *Nat Biotechnol* 2003, 21, 1171–1178.
138. Marini, D. M.; Hwang, W.; Lauffenburger, D. A.; Zhang, S.; Kamm, R. D. *Nano Lett* 2002, 2, 295–299.
139. Kisiday, J.; Jin, M.; Kurz, B.; Hung, H.; Semino, C.; Zhang, S.; Grodzinsky, A. J. *Proc Natl Acad Sci USA* 2002, 99, 9996–10001.
140. Paramonov, S. E.; Gauba, V.; Hartgerink, J. D. *Macromolecules* 2005, 38, 7555–7561.
141. O’Leary, L. E.; Fallas, J. A.; Bakota, E. L.; Kang, M. K.; Hartgerink, J. D. *Nat Chem* 2011, 3, 821–828.
142. Fallas, J. A.; Hartgerink, J. D. *Nat Commun* 2011, 3, 1087.
143. Rele, S.; Song, Y.; Apkarian, R. P.; Qu, Z.; Conticello, V. P.; Chaikof, E. L. *J Am Chem Soc* 2007, 129, 14780–14787.
144. Cejas, M. A.; Kinney, W. A.; Chen, C.; Vinter, J. G.; Almond, J., H. R.; Balss, K. M.; Maryanoff, C. A.; Schmidt, U.; Breslav, M.; Mahan, A.; Lacy, E.; Maryanoff, B. E. *Proc Natl Acad Sci USA* 2008, 105, 8513–8518.
145. Koide, T.; Homma, D. L.; Asada, S.; Kitagawa, K. *Bioorg Med Chem Lett* 2005, 15, 5230–5233.
146. Kotch, F. W.; Raines, R. T. *Proc Natl Acad Sci USA* 2006, 103, 3028–3033.
147. Johnson, G.; Jenkins, M.; McLean, K. M.; Griesser, H. J.; Kwak, J.; Goodman, M.; Steele, J. G. *J Biomed Mater Res* 2000, 51, 612–624.
148. Cejas, M. A.; Chen, C.; Kinney, W. A.; Maryanoff, B. E. *Bioconjug Chem* 2007, 18, 1025–1027.
149. Laskin, D. L.; Soltys, R. A.; Berg, R. A.; Riley, D. J. *Am J Respir Cell Mol Biol* 1990, 2, 463–470.
150. Laskin, D. L.; Soltys, R. A.; Berg, R. A.; Riley, D. J. *Am J Respir Cell Mol Biol* 1994, 10, 58–64.
151. Inoue, O.; Suzuki-Inoue, K.; Shinoda, D.; Umeda, Y.; Uchino, M.; Takasaki, S. -I.; Ozaki, Y. *FEBS Lett* 2009, 583, 81–87.
152. Hennessy, K. M.; Pollot, B. E.; Clem, W. C.; Phipps, M. C.; Sawyer, A. A.; Culpepper, B. K.; Bellis, S. L. *Biomaterials* 2009, 30, 1898–1909.
153. Chattopadhyay, S.; Murphy, C. J.; McAnulty, J. F.; Raines, R. T. *Org Biomol Chem* 2012, 10, 5892–5897.
154. Chattopadhyay, S.; Guthrie, K. M.; Teixeira, L.; Murphy, C. J.; Dubielzig, R. R.; McAnulty, J. F.; Raines, R. T. *J Tissue Eng Regen Med* 2014, 8, DOI: 10.1002/term.1886.
155. Wang, A. Y.; Mo, X.; Chen, C. S.; Yu, S. M. *J Am Chem Soc* 2005, 127, 4130–4131.
156. Wang, A. Y.; Foss, C. A.; Leong, S.; Mo, X.; Pomper, M. G.; Yu, S. M. *Biomacromolecules* 2008, 9, 1755–1763.
157. Mo, X.; An, Y.; Yun, C. -S.; Yu, S. M. *Angew Chem Int Ed* 2006, 45, 2267–2270.
158. Li, Y.; Foss, C. A.; Summerfield, D. D.; Doyle, J. J.; Torok, C. M.; Dietz, H. C.; Pomper, M. G.; Yu, S. M. *Proc Natl Acad Sci USA* 2012, 109, 14767–14772.
159. Li, Y.; Foss, C. A.; Pomper, M. G.; Yu, S. M. *J Vis Exp* 2014, e51052.

160. Holmgren, S. K.; Taylor, K. M.; Bretscher, L. E.; Raines, R. T. *Nature* 1998, 392, 666–667.
161. Hodges, J. A.; Raines, R. T. *J Am Chem Soc* 2003, 125, 9262–9263.
162. Malkar, N. B.; Lauer-Fields, J. L.; Borgia, J. A.; Fields, G. B. *Biochemistry* 2002, 41, 6054–6064.
163. Eberhardt, E. S.; Panasik, N., Jr.; Raines, R. T. *J Am Chem Soc* 1996, 118, 12261–12266.
164. Bretscher, L. E.; Jenkins, C. L.; Taylor, K. M.; DeRider, M. L.; Raines, R. T. *J Am Chem Soc* 2001, 123, 777–778.
165. Shoulders, M. D.; Satyshur, K. A.; Forest, K. T.; Raines, R. T. *Proc Natl Acad Sci USA* 2010, 106, 559–564.
166. Hodges, J. A.; Raines, R. T. *J Am Chem Soc* 2005, 127, 15923–15932.

Reviewing Editor: Gary D. Glick